Rozanolixizumab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications
Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.
Journal: Current medical research and opinion
Published: July 24, 2026
Retraction: Aseptic Meningitis Following Rozanolixizumab in a Patient With Refractory Anti-MuSK Positive Myasthenia Gravis: A Case Report.
Journal: The Neurohospitalist
Published: June 26, 2026
Inebilizumab (Uplizna) for myasthenia gravis.
Journal: The Medical letter on drugs and therapeutics
Published: June 25, 2026
Nipocalimab (Imaavy) for myasthenia gravis.
Journal: The Medical letter on drugs and therapeutics
Published: May 15, 2026
Clinical Course After a Single Cycle of Rozanolixizumab in Generalized Late-Onset Myasthenia Gravis.
Clinical Course After a Single Cycle of Rozanolixizumab in Generalized Late-Onset Myasthenia Gravis.
Journal: Journal of clinical neurology (Seoul, Korea)
Published: April 04, 2026
FcRn-Targeted Alpha Therapy Using [225Ac]Ac-Macropa-Rozanolixizumab Enables Potent Antitumor Activity.
Journal: Molecular imaging and biology
Published: March 05, 2026
Nipocalimab and other FcRn blockers in neuromuscular disorders.
Journal: Pharmacology & therapeutics
Published: March 03, 2026
Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis.
Journal: Neurology and therapy
Published: February 25, 2026
Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: February 17, 2026
Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.
Journal: Journal of neuroimmunology
Published: February 07, 2026
Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.
Journal: American journal of therapeutics
Published: January 08, 2026
Last Updated: 09/26/2026